DexCom Faces Criticism Over Alleged Inaccurate Glucose Monitoring Device

DexCom is facing allegations of providing inaccurate readings with its G7 continuous glucose monitoring device, leading to hospitalizations and deaths. The FDA inspection revealed an unauthorized design change without regulatory approval. Patients have reported inaccuracies, failures, and adhesive and connectivity issues. The competitive environment is making things tougher, with Abbott's Libre 3 product and GLP-1 treatments slowing the progression of type 2 diabetes. The report also criticizes governance, citing management exodus and the unexpected departure of CEO Kevin Sayer. The stock has fallen back to levels last seen in April.

DexCom Inc. (DXCM) is under intense scrutiny following allegations of providing inaccurate readings with its G7 continuous glucose monitoring (CGM) device, resulting in hospitalizations and deaths. A short report by Hunterbrook Media Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA^[1] revealed that the company made an unauthorized design change to the G7, which the FDA later deemed "adulterated." This change was implemented without regulatory approval and led to internal tests showing reduced accuracy across the board.

Despite the FDA's findings, DexCom sold the device, drawing scrutiny from regulatory bodies and patients alike. Patient complaints surged, with many reverting to the G6 or switching to competitors like Abbott Laboratories (ABT). The G7 has been linked to severe consequences, including at least 60 hospitalizations and multiple deaths, according to a law firm investigating the device Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA^[1].

Executives have departed amid the controversy, including CEO Kevin Sayer, who left the company abruptly. Former employees have described a culture that prioritized profits over patient safety. The report alleges that the leadership team lacked proper expertise and that the device was rushed to market to compete with Abbott Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA^[1].

DexCom's financial health has also come under scrutiny. The company has faced accounting practices under question and could face another downside surprise similar to 2024, when disappointing results triggered a sharp stock decline. The stock has fallen back to levels last seen in April, down 4.54% at $72.97 on Thursday Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA^[1].

The competitive landscape is making things tougher for DexCom. Abbott's Libre 3 and GLP-1 treatments are slowing the progression of type 2 diabetes, posing a significant threat. DexCom's G7 has received more FDA accuracy complaints than Abbott's competing product Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA^[1].

In response to these allegations, DexCom has yet to provide a public comment. Hunterbrook Media has shared its probe with a senior official from the Health and Human Services (HHS) and requested FDA intervention DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device^[2].

References

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA^[1] https://www.benzinga.com/markets/large-cap/25/09/47742074/short-report-alleges-dexcom-sold-faulty-g7-device-cited-by-fda
DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device^[2] https://stocktwits.com/news-articles/markets/equity/dexcom-stock-slumps-after-hunterbrook-media-investigation-raises-concerns-about-its-g7-device/chD3f5NR3Tm